Genworth Financial (GNW) Q3 2025 earnings summary

Executive summary

• Net income for Q3 2025 was $116 million ($0.28 per diluted share), up 36% year-over-year; adjusted operating income was $17 million ($0.04 per share), down from $48 million in Q3 2024, driven by strong Enact performance and investment gains.

• Enact contributed $134 million in adjusted operating income and returned $110 million in capital, totaling $1.2 billion since its 2021 IPO.

• CareScout expanded its Quality Network to over 700 providers, completed the Seniorly acquisition, and launched its first standalone LTC insurance product.

• Share repurchases totaled $76 million in Q3, with $696 million executed since program inception and a new $350 million authorization announced.

• Continued execution of strategic priorities: value creation via Enact, stabilizing legacy LTC/annuity businesses, and growth through CareScout.

Financial highlights

• Total revenues for Q3 2025 were $1.94 billion, up 3% year-over-year; net investment income rose 3% to $799 million, and net investment gains were $99 million.

• Adjusted operating income was $17 million for Q3 2025, with Enact as the primary driver; net income of $116 million.

• Long-term care insurance segment posted an adjusted operating loss of $100 million due to higher benefit utilization and lower terminations.

• Life and annuities reported $4 million in adjusted operating income; annuities contributed $19 million, life insurance had a $15 million loss.

• Ended the quarter with $254 million in cash and liquid assets; U.S. life insurance companies' RBC ratio at 303%.

Outlook and guidance

• Enact expects to return approximately $500 million to shareholders in 2025; Genworth anticipates receiving $405 million based on its 81% stake.

• Share repurchase allocation for 2025 is projected at $200–$225 million, with flexibility based on performance and market conditions.

• Continued investment in CareScout, with $45–$50 million planned for 2025, excluding the $15 million Seniorly acquisition.

• Management expects continued volatility in long-term care insurance results due to assumption updates and actual experience.

• Ongoing focus on MIRAP for LTC, with higher rate increase approvals expected in Q4.